| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2017-04-18 |
Bavarian Nordic (Denmark) Valneva (France - Austria) |
EB66® cell line |
|
licensing |
Technology - Services - Infectious diseases |
Licensing agreement |
| 2017-04-18 |
Ionis Pharmaceuticals (USA - CA) Suzhou Ribo Life Science (China) |
up to three Generation 2+ antisense drugs |
|
collaboration - licensing - development - commercialisation |
Cancer - Oncology - Metabolic diseases |
Licensing agreement |
| 2017-04-18 |
Ipsen (France) |
chief scientific officer |
|
nomination |
|
Nomination |
| 2017-04-18 |
Cobra Biologics (Sweden) |
- UK viral vector manufacturing capabilities and Sweden DNA plasmid production and characterisation capabilities
|
|
construction of new premises |
Technology - Services |
Construction of new premises |
| 2017-04-18 |
Faron Pharmaceuticals (Finland) University of Birmingham Medical School (UK) |
Clevegen® |
liver cancer |
clinical research |
Cancer - Oncology |
Clinical research agreement |
| 2017-04-17 |
HTG Molecular Diagnostics (US - AZ) Centre Léon Bérard (France) |
characterization of immunologic profiles from advanced malignant tumor samples collected in the ProfiLER study |
|
R&D - research |
Cancer - Oncology - Technology - Services |
Research agreement |
| 2017-04-17 |
HTG Molecular Diagnostics (USA - AZ) Daiichi Sankyo (Japan) |
custom assay for the detection of mRNA targets using the HTG EdgeSeq technology |
|
services |
Cancer - Oncology - Technology - Services |
Services contract |
| 2017-04-17 |
Amarantus BioScience (USA – CA) Elto Pharma (USA – CA) |
|
|
establishment of a new subsidiary in the US |
CNS diseases |
Establishment of a new subsidiary in the US |
| 2017-04-17 |
Amarantus BioScience (USA – CA) MANF Therapeutics (USA – CA) |
MANF Therapeutics (USA – CA) |
retinitis pigmentosa, retinal artery occlusion, glaucoma, Parkinson's disease |
establishment of a new subsidiary in the US |
Ophtalmological diseases - Neurodegenerative diseases |
Establishment of a new subsidiary in the US |
| 2017-04-17 |
Juno Therapeutics (USA - WA) |
|
|
nomination |
|
Nomination |
| 2017-04-17 |
Crispr Therapeutics (Switzerland - UK) Casebia Therapeutics (UK) StrideBio (USA - NC) |
AAV vectors |
|
collaboration, licensing |
Technology - Services |
Collaboration agreement |
| 2017-04-17 |
Juno Therapeutics (USA - WA) |
president of R&D |
|
nomination |
Cancer - Oncology |
Nomination |
| 2017-04-16 |
Ionis Pharmaceuticals (USA - CA) Akcea Therapeutics (USA - CA), a subsidiary of Ionis Pharmaceuticals (USA - CA) |
inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx |
hereditary transthyretin amyloidosis (hATTR) |
licensing |
Rare diseases - Genetic diseases |
Licensing agreement |
| 2017-04-13 |
Abbvie (USA - IL) Argen-X (Belgium) |
ARGX-115 |
|
development, commercialisation |
Cancer - Oncology |
Milestone |
| 2017-04-13 |
BMS (USA - NY) Biogen (USA - CA) |
BMS-986168 |
progressive supranuclear palsy |
licensing |
Rare diseases - Neurodegenerative diseases - Neurological diseases |
Licensing agreement |
| 2017-04-13 |
BMS (USA - NY) Roche (Switzerland) |
BMS-986089 |
Duchenne muscular dystrophy (DMD) |
licensing |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Licensing agreement |
| 2017-04-13 |
Recordati (Italy) |
Recordati Rare Diseases Canada |
|
establishment of a new subsidiary |
Rare diseases |
Establishment of a new subsidiary in the US |
| 2017-04-13 |
Sensorion (France) |
|
|
nomination |
Otorhinolaryngology |
Nomination |
| 2017-04-11 |
Novartis (Switzerland) |
new production plant in Prevalje (Slovenia) |
|
construction of new premises |
|
Construction of new premises |
| 2017-04-11 |
BMS (USA - NY) Apexigen (USA - CA) |
Opdivo® (nivolumab) and APX005M |
second-line metastatic NSCLC patients who have failed prior chemotherapy, metastatic melanoma patients who have failed prior I-O therapy |
clinical research |
Cancer - Oncology |
Clinical research agreement |
